Labcorp Holdings Inc. ($LH)

HR8260 is a procedural early-stage bill with zero funding authorization and no market-moving catalyst. No price action has been observed in LH ($260.86) or DGX ($193.96) related to this legislation. The bill has only been referred to committee; passage probability is low at this time.

→ If enacted, creates a new mandated test volume for Lp(a) and ApoB assays with zero patient out-of-pocket cost, potentially increasing total test utilization for the indicated at-risk population.

The Combating Illicit Xylazine Act (S545) is a drug scheduling bill that reclassifies xylazine as a Schedule III controlled substance. It authorizes no new funding, tax incentives, or procurement programs, resulting in negligible market impact for retail-investor-relevant publicly traded companies.

The CARE Act of 2025 (S.3145) requires CMS to test a Medicare payment model for ground ambulance dispatches that do not result in transport, creating a new revenue stream for ambulance providers and ancillary services. While only introduced and referred to committee, the bipartisan sponsorship and House companion bill provide credible legislative momentum. Evolent Health ($EVH) and Labcorp ($LH) are positioned as indirect beneficiaries through care coordination platforms and diagnostic lab services, respectively. The bill has no explicit funding authorization — it mandates a model test, not direct appropriations.

→ Expands the settings in which Medicare reimburses diagnostic lab services, potentially increasing utilization of point-of-care and remote lab testing in emergency scenarios where patients are treated on-site rather than transported.

HR 3037 (Access to Breast Cancer Diagnosis Act) is an early-stage bill eliminating patient cost-sharing for diagnostic breast exams. The bill benefits diagnostic imaging providers $DGX and $LH through higher utilization, while insurers face increased claims costs. Passage is uncertain at this procedural stage, but bipartisan cosponsorship and a companion Senate bill signal moderate legislative momentum.

→ Removal of cost-sharing lowers the financial barrier for patients to obtain diagnostic breast imaging, leading to increased utilization of these services.

S.3607 expands Medicare Part B to cover genetic counseling as a new provider category effective Jan 1, 2027, directly increasing the addressable patient population for genetic testing. This is a structural positive for Labcorp ($LH) and Quest Diagnostics ($DGX) through higher test volume, and for AMN Healthcare ($AMN) through increased demand for scarce genetic counselors. The bill is at early legislative stage (referred to Finance Committee) with companion bill HR6280 in the House.

→ Medicare beneficiaries can now access and bill for genetic counseling services from licensed/certified genetic counselors as a covered benefit, removing a prior barrier where services had to be furnished by or incident to a physician; this expands the addressable patient population for genetic testing orders that typically follow counseling

HR6897 (Thyroid Disease CARE Act) authorizes $30M/year for five years for thyroid disease research and improved diagnostics. The bill is in early stage — referred to House Energy and Commerce Committee on December 18, 2025. Real market data shows diagnostic stocks trending negative over the past 30 days, with Labcorp down 1.53% and Abbott down 11.85%. Any impact is procedural and speculative at this stage.

→ Federal grants and contracts will be issued for thyroid disease diagnostic research and improved diagnostic techniques

The PrEP and PEP are Prevention Act (HR5127) mandates zero-cost coverage of HIV prevention drugs and associated lab monitoring across all US insurance programs. This early-stage bipartisan bill creates direct volume upside for Gilead ($GILD) on branded PrEP, Viatris ($VTRS) on generic PrEP, and Labcorp ($LH) on mandatory diagnostic services. Merck ($MRK) is excluded from the causal chain because its islatravir candidate is not FDA-approved and the bill only covers approved drugs.

→ Insurers must cover routine lab monitoring for PrEP patients (HIV antigen/antibody tests, creatinine, STI panels) at zero cost-sharing, effectively removing the patient-side barrier to testing adherence and increasing the total volume of billable lab services per patient.

The SCREENS for Cancer Act reauthorizes and expands national cancer screening programs for 2026-2030. This creates a structural volume tailwind for Labcorp ($LH) and Quest Diagnostics ($DGX) as the primary processors of screening lab work. Both stocks have been down over the past month on broader market weakness, not bill-specific news — the authorization provides a real federal program pipeline for incremental testing revenue once appropriations are secured.

→ Increased volume of breast and cervical cancer screening lab tests reimbursed through the program, which serves over 6.4M people historically and is expected to expand

The RESULTS Act (S.2761) proposes shifting Medicare Part B lab test payment rate data collection from CMS to an independent nonprofit, targeting the key revenue risk for $LH and $DGX under PAMA. The bill is early-stage (referred to committee) and faces a multi-year path, but its mechanism directly addresses a structural headwind that has driven ~10% cumulative Medicare rate cuts since 2018. Real market data shows a 5-day selloff in both tickers — $LH dropped from $270.68 to $263.99 and $DGX from $195.02 to $195.64 — creating an entry point for investors betting on legislative momentum for reimbursement stability.

→ Shifts the data source used to calculate private payor-based fee schedule rates from a CMS-mandated reporting system (which has led to steep, unpredictable rate cuts) to a qualified independent nonprofit database. This reduces the risk of CMS-administrative errors and data-weighting imbalances that have caused 10-15% cumulative PAMA cuts since 2018.

HR3482 is a procedural authorization bill requiring the VA to build an online scheduling system for community care appointments. It mandates an IT system change but includes no explicit funding, and it does not directly increase patient volume or reimbursement rates. The market impact on healthcare stocks ($DGX, $LH, $HCA, $UHS, $AMN) is negligible in the near term.

HR2004 'Tyler’s Law' is a procedural early-stage bill directing HHS to study fentanyl testing in emergency departments. It authorizes zero funding, imposes no mandates, and has languished in committee for over a year with no further action, producing no near-term market impact for any public company.

S. 800 (Precision Brain Health Research Act of 2025) expands the VA's biomarker research mandate but authorizes zero new funding. The bill is reported out of committee and awaiting floor action. Labcorp ($LH at $262.63) and Quest Diagnostics ($DGX at $194.98) show no legislative catalyst in their recent price trends—both are down ~0.5-1.6% over the last 30 days. No near-term market impact.

→ VA must expand its biomarker research program scope but has no new appropriations to fund external contracts; any future diagnostic service contracts would require separate appropriations legislation.

HR3951 expands and extends the VA's contracted disability exam program through 2031, a procedural positive for outsourced exam providers like Labcorp ($LH). However, the bill authorizes no new funding and is early-stage (reported out of committee), with actual contract volume dependent on future VA appropriations. $LH has underperformed the market recently, closing at $264.19 on 2026-04-30 with a -0.98% 30-day return, indicating broader headwinds.

→ Broadens the pool of professionals Labcorp can contract for VA disability exams, potentially increasing contract volume without requiring additional licensure waivers per state

HR6178, introduced in November 2025 and referred to two committees, mandates no-cost lung cancer screenings and expanded tobacco cessation services under Medicaid, Medicare, and private insurance. This creates a direct revenue tailwind for diagnostic lab companies $LH and $DGX through increased test volume, and a pharmacy/PBM benefit for $CVS through mandated tobacco cessation drug coverage. Health insurers ($UNH, $HUM, $CNC, $MOH) face a neutral cost burden from the coverage mandate and prior authorization ban, with manageable MLR impact given the preventive nature of the service. The bill is early-stage with no appropriation attached.

→ Creates a new guaranteed revenue stream for diagnostic testing companies by increasing the addressable patient pool for lung cancer screenings (low-dose CT scans) and related lab work. The no-cost-sharing provision removes a demand-side barrier, directly increasing utilization rates among current beneficiaries.

The SUPPORT for Patients and Communities Reauthorization Act (P.L. 119-44) became law on December 1, 2025, extending federal substance use disorder and mental health funding through FY2030. This creates a structural tailwind for diagnostic testing (LH, DGX) and pharmaceutical distribution (CAH) via sustained grant programs, while also providing a positive policy backdrop for psychedelic therapy developers (CMPS, MNMD). Recent market data shows diagnostic stocks declining over the past 30 days, with LH at $261.79 (-1.88% 30d) and DGX at $193.52 (-1.26% 30d), suggesting the market has not yet priced in this long-term authorization catalyst.

→ Sustained federal grant funding for diagnostic testing services for at least five additional years maintains testing volume floors for contract laboratories.

HR1406 (Lung Cancer Screening and Prevention Act of 2025) would expand Medicare coverage to FDA-approved lung cancer screening tests beyond the current USPSTF-recommended set. The bill is in early committee stage with no authorized funding, limiting near-term market impact. GEHC, LH, and DGX are structural beneficiaries if passed, but passage is uncertain and distant.

→ CMS must set coverage and payment limits for additional lung cancer screening tests; screening volumes for diagnostic imaging and lab testing increase as Medicare beneficiaries gain access to a broader set of FDA-cleared tests

HR7868, the 'Expanding Support for Living Donors Act of 2026,' is an early-stage bill authorizing up to $10,000 per donor for qualifying expenses in FY2027. Actual appropriations are required. The market reaction in diagnostic ($LH, $DGX) and device ($MDT, $SYK) stocks is currently driven by broader market trends — all four stocks are down 2-9% over the past 30 days — not by this bill's introduction. The legislative impact on revenue is negligible at this stage.

→ Increased volume of donor pre-screening and post-operative diagnostic lab tests reimbursed under the program, potentially raising test utilization by living donors

The RESULTS Act (HR5269) is an early-stage bill aiming to stabilize Medicare reimbursement for clinical diagnostic lab tests by improving data accuracy. It has 77 cosponsors and a companion bill in the Senate but remains in committee with no near-term market impact. Real market data shows LH at $259 and DGX at $190.19, both down ~3% over 30 days, reflecting sector headwinds unrelated to this procedural legislation.

→ the bill modifies data collection requirements for widely available non-advanced diagnostic lab tests, potentially altering the data inputs that determine the weighted median private payor rate used to set Medicare payment for these tests

The ASAP Act (HR6130) mandates Medicare coverage for FDA-cleared blood-based dementia screening tests starting Jan 1, 2028. Labcorp ($LH) and Quest Diagnostics ($DGX) are the two largest independent lab operators with existing FDA-cleared blood-based dementia tests, making them primary beneficiaries of this new mandatory benefit category. The bill is in early legislative stages (referred to committee) with companion bill S3267 in the Senate, but the bipartisan sponsorship and 82 cosponsors indicate strong momentum for a mid-2027 passage timeline.

→ Creates a new, permanent Medicare-covered diagnostic category for blood-based dementia tests, driving a large increase in testing volume among the 65+ Medicare population (currently ~60 million beneficiaries). Labcorp's existing FDA-cleared blood-based dementia test (e.g., the amyloid tau neurofilament light chain panel) gains a guaranteed reimbursement pathway.

The 'Supporting Healthy Moms and Babies Act' (HR3762) is an early-stage bill that would mandate comprehensive maternity/newborn care coverage without cost-sharing under ACA plans. With 28 cosponsors, a companion bill in the Senate, and referral to three committees, legislative progress is early but has nominal bipartisan support. Insurers UNH and CI face increased medical costs, while diagnostic labs LH and DGX benefit from higher utilization. No dollar amount is authorized or appropriated.

→ Increased volume of diagnostic lab tests ordered by providers during pregnancy and postpartum due to removal of cost-sharing barrier, expanding addressable market for lab services.

The CHOICE for Veterans Act of 2025 (HR3132) is awaiting floor action after being reported out of committee. This bill expands fee agreements for VA benefits claims, which is expected to improve claims efficiency and reimbursement rates for healthcare providers serving veterans. Companies like HCA Healthcare ($HCA), Universal Health Services ($UHS), Labcorp Holdings ($LH), and Quest Diagnostics ($DGX) are positioned to benefit from these operational improvements.

→ Increases revenue opportunities for legal and claims assistance services, leading to more efficient and potentially higher quality claim submissions for VA benefits. This improves the likelihood and speed of reimbursement for healthcare providers.

The Find It Early Act (S.1410), introduced in April 2025, would mandate no-cost-sharing coverage for advanced breast imaging for high-risk individuals and those with dense breast tissue. The bill is in early legislative stages (referred to committee) with no funding authorized. Real market data shows GEHC has fallen 14.88% in the last 7 days to $59.49, near its 52-week low, while UNH has surged 41.62% over 30 days to $370.74—moves driven by factors unrelated to this early-stage bill.

→ Labcorp experiences increased imaging utilization from the expanded eligible patient population, driving volume growth in its diagnostics segment.

The Reducing Hereditary Cancer Act (HR4752) mandates Medicare coverage for germline mutation testing—a direct expansion of the addressable market for genetic diagnostics companies. The bill is in early committee stage (referred to Energy & Commerce and Ways & Means), with a Senate companion bill (S2760) also introduced. Real market data shows genetic testing/ diagnostics tickers have declined 0.09% to 5.12% in the past week, but this bill represents structural demand expansion independent of recent price action.

→ Test volume for hereditary cancer panels (e.g., Labcorp's Inherited Cancer Panel) increases among Medicare beneficiaries, expanding a revenue stream currently limited to commercial insurance and self-pay.

S. 339 authorizes Medicare coverage for FDA-approved multi-cancer early detection screening tests starting in 2028, creating a new government-reimbursed revenue stream for diagnostic companies. The bill is in early legislative stages (referred to committee since Jan 2025) with 68 cosponsors and an identical House companion that has advanced further. Pure-play liquid biopsy developers and reference laboratories with processing infrastructure are positioned to benefit.

→ Labcorp, as one of the two largest national reference laboratories, can negotiate test administration agreements with test developers and directly bill Medicare for testing services, capturing margin on test processing.